Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease

Key Points Question Can fyn inhibition by AZD0530 slow the decline in relative cerebral metabolic rate for glucose and the change in secondary end points in cognition, function, and other biomarkers in participants with mild Alzheimer dementia? Findings In this multicenter randomized clinical trial of 159 participants with mild Alzheimer dementia, AZD0530 treatment did not differ from placebo in slowing cerebral metabolic decline in an Alzheimer disease–associated prespecified statistical region of interest. Secondary end points revealed no treatment effects on the rate of change in cognition, function, and other biomarkers but revealed trends for slowing the decrease in hippocampal volume and entorhinal thickness. Meaning Although this trial found no statistically significant effects of AZD0530 treatment on the relative cerebral metabolic rate for glucose or on secondary clinical or biomarker measures, it provides support for cerebral metabolic rate for glucose, as measured by 18F-fluorodeoxyglucose positron emission tomography, as a statistically powerful outcome measure that is well correlated with clinical outcomes.

[1]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[2]  M. Sano,et al.  A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease , 2011, Neurology.

[3]  George Perry.  Faculty Opinions recommendation of The prion protein as a receptor for amyloid-beta. , 2010 .

[4]  Michael W. Weiner,et al.  Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative , 2010, NeuroImage.

[5]  J. Collinge,et al.  Prion Protein as a Toxic Acceptor of Amyloid-β Oligomers , 2018, Biological Psychiatry.

[6]  H. Nygaard.  Targeting Fyn Kinase in Alzheimer’s Disease , 2018, Biological Psychiatry.

[7]  H. Soininen,et al.  Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology , 2016, Molecular Psychiatry.

[8]  A. Aguzzi,et al.  Supplementary figure legends , 2010 .

[9]  J. Baselga,et al.  Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study. , 2012, Bone.

[10]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[11]  A. Vortmeyer,et al.  Alzheimer Amyloid-β Oligomer Bound to Post-Synaptic Prion Protein Activates Fyn to Impair Neurons , 2012, Nature Neuroscience.

[12]  A. Fagan,et al.  SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease , 2010, PLoS genetics.

[13]  J. Yesavage,et al.  Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. , 1986 .

[14]  J. Watanabe,et al.  First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours , 2013, Investigational New Drugs.

[15]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[16]  J. Laplanche,et al.  Neuron Dysfunction Is Induced by Prion Protein with an Insertional Mutation via a Fyn Kinase and Reversed by Sirtuin Activation in Caenorhabditis elegans , 2010, The Journal of Neuroscience.

[17]  R. C. Macridis.  A review , 1963 .

[18]  W. Klein,et al.  Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[19]  W. Surewicz,et al.  Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. , 2010, The Journal of biological chemistry.

[20]  T. Karrison,et al.  Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma , 2013, Investigational New Drugs.

[21]  R. Petersen,et al.  Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer's Disease Assessment Scale That Broaden Its Scope , 1997, Alzheimer disease and associated disorders.

[22]  Alun Williams,et al.  Amyloid-β-induced Synapse Damage Is Mediated via Cross-linkage of Cellular Prion Proteins , 2011, The Journal of Biological Chemistry.

[23]  G. V. Van Hoesen,et al.  Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease , 2004, The Journal of Neuroscience.

[24]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[25]  R. Dalton,et al.  Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects. , 2010, Anticancer research.

[26]  A. Vortmeyer,et al.  Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein , 2013, Neuron.

[27]  Margaret A. Pericak-Vance,et al.  Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias , 2014, PLoS genetics.

[28]  S. Strittmatter,et al.  Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein , 2010, The Journal of Neuroscience.

[29]  Michael W. Salter,et al.  Src kinases: a hub for NMDA receptor regulation , 2004, Nature Reviews Neuroscience.

[30]  Alan C. Evans,et al.  A nonparametric method for automatic correction of intensity nonuniformity in MRI data , 1998, IEEE Transactions on Medical Imaging.

[31]  L. Mucke,et al.  Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice , 2004, The Journal of Neuroscience.

[32]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[33]  Sheila M. Thomas,et al.  Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.

[34]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  W. Klein,et al.  Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.

[36]  Stephen W. Scheff,et al.  Quantitative assessment of cortical synaptic density in Alzheimer's disease , 1990, Neurobiology of Aging.

[37]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[38]  Shaomin Li,et al.  Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake , 2009, Neuron.

[39]  L. Seymour,et al.  A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer , 2012, Investigational New Drugs.

[40]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[41]  L. Mucke,et al.  Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.

[42]  D. Westaway,et al.  Aβ Inhibition of Ionic Conductance in Mouse Basal Forebrain Neurons Is Dependent upon the Cellular Prion Protein PrPC , 2011, The Journal of Neuroscience.

[43]  Eric M. Reiman,et al.  Brain Imaging in the Evaluation of Putative Alzheimer’s Disease-Slowing, Risk-Reducing and Prevention Therapies , 2009 .

[44]  L. Mucke,et al.  Amyloid-beta / Fyn – Induced Synaptic , Network , and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer ’ s Disease , 2015 .

[45]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[46]  L. Mucke,et al.  Fyn Kinase Induces Synaptic and Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[47]  S. Yen,et al.  Disease-related Modifications in Tau Affect the Interaction between Fyn and Tau* , 2005, Journal of Biological Chemistry.

[48]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[49]  T. Hunter.  A tail of two src's: Mutatis mutandis , 1987, Cell.

[50]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[51]  Nick C Fox,et al.  Acceleration of cortical thinning in familial Alzheimer's disease , 2011, Neurobiology of Aging.

[52]  C. Jack,et al.  Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.

[53]  C. Jack,et al.  Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia , 2002, Neurology.

[54]  Ben A. Barres,et al.  Complement and microglia mediate early synapse loss in Alzheimer mouse models , 2016, Science.

[55]  Anders M. Dale,et al.  Reliability in multi-site structural MRI studies: Effects of gradient non-linearity correction on phantom and human data , 2006, NeuroImage.

[56]  M. Rowan,et al.  Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites , 2011, Nature communications.

[57]  S. Strittmatter,et al.  Fyn inhibition rescues established memory and synapse loss in Alzheimer mice , 2015, Annals of neurology.

[58]  Hyoung-Gon Lee,et al.  Amyloid-β42 Interacts Mainly with Insoluble Prion Protein in the Alzheimer Brain* , 2011, The Journal of Biological Chemistry.

[59]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[60]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[61]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[62]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[63]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[64]  D. Berman,et al.  Oligomeric amyloid-β peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism , 2008, Nature Neuroscience.

[65]  E. Kandel,et al.  Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. , 1992, Science.

[66]  Kewei Chen,et al.  A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease , 2015, Alzheimer's Research & Therapy.

[67]  S. Strittmatter,et al.  Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an alzheimer's disease model mouse , 2010, BMC Neuroscience.

[68]  S. Lindquist,et al.  The cellular prion protein mediates neurotoxic signalling of β‐sheet‐rich conformers independent of prion replication , 2011, The EMBO journal.

[69]  B. Ogles,et al.  A multiperspective, multivariable evaluation of reliable change. , 1998, Journal of consulting and clinical psychology.

[70]  L. Mucke,et al.  Ablation of Cellular Prion Protein Does Not Ameliorate Abnormal Neural Network Activity or Cognitive Dysfunction in the J20 Line of Human Amyloid Precursor Protein Transgenic Mice , 2011, The Journal of Neuroscience.

[71]  B. Reisberg,et al.  MRI and CSF studies in the early diagnosis of Alzheimer's disease , 2004, Journal of internal medicine.

[72]  Graeme Milligan,et al.  Identification of a serotonin/glutamate receptor complex implicated in psychosis , 2008, Nature.

[73]  G. Alexander,et al.  Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[74]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[75]  Michael Weiner,et al.  Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. , 2010, JAMA.

[76]  S. Strittmatter,et al.  Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[77]  S. Yen,et al.  Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy , 2010, Neuropathology and applied neurobiology.

[78]  H. Mackay,et al.  A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium , 2012, Investigational New Drugs.

[79]  Gunhild Waldemar,et al.  Rates of Cognitive Change in Alzheimer Disease: Observations Across a Decade of Placebo-controlled Clinical Trials With Donepezil , 2009, Alzheimer disease and associated disorders.

[80]  W. Hargreaves,et al.  Assessment of client/patient satisfaction: development of a general scale. , 1979, Evaluation and program planning.

[81]  M. Mintun,et al.  Amyloid deposition, hypometabolism, and longitudinal cognitive decline , 2012, Annals of neurology.

[82]  Anders M. Dale,et al.  Nonlinear registration of longitudinal images and measurement of change in regions of interest , 2011, Medical Image Anal..

[83]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[84]  J. Baselga,et al.  Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors , 2010, Clinical Cancer Research.

[85]  Ronald Killiany,et al.  Structural Magnetic Resonance Imaging in Established and Prodromal Alzheimer Disease: A Review , 2003, Alzheimer disease and associated disorders.

[86]  Mark D'Esposito,et al.  Imaging the aging brain , 2009 .

[87]  T. Suzuki,et al.  NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. , 1995, Biochemical and biophysical research communications.

[88]  T. L. Brink,et al.  Clinical Gerontology: A Guide to Assessment and Intervention , 1986 .

[89]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[90]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[91]  S. Komai,et al.  Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor. , 2001, The Journal of biological chemistry.

[92]  L. Luncz,et al.  Regulation of Embryonic Cell Adhesion by the Prion Protein , 2009, PLoS biology.

[93]  Jennifer Farmer,et al.  Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease , 2005, Annals of neurology.

[94]  M. Pangalos,et al.  Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia , 2009, Journal of Pharmacology and Experimental Therapeutics.

[95]  J. Kaye,et al.  Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease , 2012, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[96]  J. Cummings,et al.  The Neuropsychiatric Inventory , 1997, Neurology.

[97]  B. Strooper,et al.  Modulation of γ- and β-Secretases as Early Prevention Against Alzheimer’s Disease , 2018, Biological Psychiatry.

[98]  L. Otterbein,et al.  N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. , 2006, Journal of medicinal chemistry.

[99]  D. Bennett,et al.  The Complex PrPc-Fyn Couples Human Oligomeric Aβ with Pathological Tau Changes in Alzheimer's Disease , 2012, The Journal of Neuroscience.

[100]  H. Band,et al.  Tau interacts with src-family non-receptor tyrosine kinases. , 1998, Journal of cell science.

[101]  E. Kandel,et al.  Higher seizure susceptibility and enhanced tyrosine phosphorylation of N-methyl-D-aspartate receptor subunit 2B in fyn transgenic mice. , 1998, Learning & memory.

[102]  Jeih-San Liow,et al.  Qualitative and Quantitative Evaluation of Six Algorithms for Correcting Intensity Nonuniformity Effects , 2001, NeuroImage.

[103]  S. Strittmatter,et al.  Oligomers of Amyloid β Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease* , 2016, The Journal of Biological Chemistry.

[104]  Kai Chang,et al.  The Synaptic Localization of NR2B-Containing NMDA Receptors Is Controlled by Interactions with PDZ Proteins and AP-2 , 2005, Neuron.

[105]  A. Dale,et al.  Subregional neuroanatomical change as a biomarker for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[106]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[107]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[108]  C. Attkisson,et al.  Enhancing the utilization of outpatient mental health services , 2004, Community Mental Health Journal.

[109]  Chau Dang,et al.  Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. , 2011, Clinical breast cancer.

[110]  R. Katzman.,et al.  Pathological verification of ischemic score in differentiation of dementias , 1980, Annals of neurology.

[111]  M. Sano,et al.  An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.

[112]  R. Shen,et al.  Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). , 2011, Anticancer research.

[113]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[114]  S. Strittmatter,et al.  Fyn kinase inhibition as a novel therapy for Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[115]  C. Dyck.  Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise , 2018 .

[116]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[117]  Bernardo L Sabatini,et al.  Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway , 2007, The Journal of Neuroscience.